TWI849310B - 用於腫瘤微環境免疫調節作用之組蛋白去乙醯化酶抑制劑 - Google Patents

用於腫瘤微環境免疫調節作用之組蛋白去乙醯化酶抑制劑 Download PDF

Info

Publication number
TWI849310B
TWI849310B TW110115446A TW110115446A TWI849310B TW I849310 B TWI849310 B TW I849310B TW 110115446 A TW110115446 A TW 110115446A TW 110115446 A TW110115446 A TW 110115446A TW I849310 B TWI849310 B TW I849310B
Authority
TW
Taiwan
Prior art keywords
gntbm
compound
cells
formula
combination
Prior art date
Application number
TW110115446A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200557A (zh
Inventor
陳嘉雄
楊牧軒
吳奕宏
朱思澔
周承翰
趙月秀
陳嘉南
Original Assignee
華上生技醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 華上生技醫藥股份有限公司 filed Critical 華上生技醫藥股份有限公司
Publication of TW202200557A publication Critical patent/TW202200557A/zh
Application granted granted Critical
Publication of TWI849310B publication Critical patent/TWI849310B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110115446A 2020-04-30 2021-04-28 用於腫瘤微環境免疫調節作用之組蛋白去乙醯化酶抑制劑 TWI849310B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018427P 2020-04-30 2020-04-30
US63/018,427 2020-04-30

Publications (2)

Publication Number Publication Date
TW202200557A TW202200557A (zh) 2022-01-01
TWI849310B true TWI849310B (zh) 2024-07-21

Family

ID=78373345

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110115446A TWI849310B (zh) 2020-04-30 2021-04-28 用於腫瘤微環境免疫調節作用之組蛋白去乙醯化酶抑制劑

Country Status (15)

Country Link
US (2) US11672788B2 (enExample)
EP (1) EP4142733B1 (enExample)
JP (1) JP7748392B2 (enExample)
KR (1) KR20230005939A (enExample)
CN (1) CN116033904A (enExample)
AU (1) AU2021265994B2 (enExample)
BR (1) BR112022022015A2 (enExample)
ES (1) ES3051512T3 (enExample)
HR (1) HRP20251279T1 (enExample)
IL (1) IL297687A (enExample)
MX (1) MX2022013634A (enExample)
PL (1) PL4142733T3 (enExample)
TW (1) TWI849310B (enExample)
WO (1) WO2021219040A1 (enExample)
ZA (1) ZA202212650B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322171B (zh) * 2022-08-30 2023-03-17 深圳微芯生物科技股份有限公司 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物
CN122036601A (zh) * 2024-11-15 2026-05-15 深圳微芯生物科技股份有限公司 一种苯甲酰胺类衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
CN106916100A (zh) * 2014-04-04 2017-07-04 深圳微芯生物科技有限责任公司 一种e构型苯甲酰胺类化合物及其药用制剂
TW201934143A (zh) * 2018-01-05 2019-09-01 華上生技醫藥股份有限公司 用於調節腫瘤微環境和免疫療法的藥物組合和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
CA2552279C (en) * 2003-12-02 2014-07-15 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
CA2702536A1 (en) 2007-10-10 2009-04-16 Orchid Research Laboratories Limited Novel histone deacetylase inhibitors
CN106916101B (zh) 2017-02-15 2020-05-01 聚缘（上海）生物科技有限公司 Nampt/hdac双靶点抑制剂及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
CN106916100A (zh) * 2014-04-04 2017-07-04 深圳微芯生物科技有限责任公司 一种e构型苯甲酰胺类化合物及其药用制剂
TW201934143A (zh) * 2018-01-05 2019-09-01 華上生技醫藥股份有限公司 用於調節腫瘤微環境和免疫療法的藥物組合和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 , G DONG, et al., "Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors", J. Med. Chem., 60, ACS Publications, 2017: 7965~7983. *

Also Published As

Publication number Publication date
ES3051512T3 (en) 2025-12-29
JP2023524230A (ja) 2023-06-09
JP7748392B2 (ja) 2025-10-02
CN116033904A (zh) 2023-04-28
US12213971B2 (en) 2025-02-04
EP4142733C0 (en) 2025-10-01
EP4142733A4 (en) 2023-03-08
IL297687A (en) 2022-12-01
KR20230005939A (ko) 2023-01-10
HRP20251279T1 (hr) 2025-12-05
CA3176748A1 (en) 2021-11-04
US11672788B2 (en) 2023-06-13
WO2021219040A1 (en) 2021-11-04
TW202200557A (zh) 2022-01-01
US20230263790A1 (en) 2023-08-24
ZA202212650B (en) 2024-04-24
US20210379032A1 (en) 2021-12-09
PL4142733T3 (pl) 2026-01-19
AU2021265994B2 (en) 2024-02-29
MX2022013634A (es) 2022-11-16
NZ794355A (en) 2026-02-27
EP4142733A1 (en) 2023-03-08
BR112022022015A2 (pt) 2022-12-13
AU2021265994A1 (en) 2022-12-15
EP4142733B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
JP6342392B2 (ja) 置換型ピラゾロン化合物及び使用方法
CN103565653B (zh) 取代的吡唑酮化合物及其使用方法和用途
WO2019074116A1 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
KR20170044097A (ko) 히스톤 탈아세틸화효소 저해제에 의한 백혈병의 치료
US12023333B2 (en) Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators
US12213971B2 (en) Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
US20240197703A1 (en) Azalactam Compounds as HPK1 Inhibitors
CA3176748C (en) Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
RU2854218C1 (ru) Ингибиторы гистондеацетилазы для иммуномодуляции в микросреде опухоли
EP4719607A1 (en) Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
HK40092030A (en) Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
JP2025069098A (ja) チロシンキナーゼ阻害剤及びその使用
BR102024021500A2 (pt) Composto, composição farmacêutica e métodos para suprimir a angiogênese, para suprimir a metástase, para suprimir a oncogênese, para modular as atividades de regulação imunológica, para tratar ou prevenir uma doença e para tratar tumores ou cânceres
HK40119333A (en) Tyrosine kinases inhibitors and uses thereof
KR20240110971A (ko) 화합물